(Sharecast News) - Commercial-stage biopharmaceuticals company Amryt Pharma announced the signing of multi-regional distribution agreements with Medison Pharma on Thursday.
The AIM-traded firm said the agreement would see the distribution of 'Juxtapid', or lomitapide, in Canada. and 'Lojuxta', or lomitapide, and 'Myalept', or metreleptin, in Israel.
"Today's announcement is another positive development as we continue to grow our commercial assets in existing and new territories and we further progress towards our goal of becoming a global leader in rare and orphan diseases," said chief executive officer Dr Joe Wiley.
"We are excited to be working with Medison to leverage their expertise and presence in these territories."
At 1254 GMT, shares in Amryt Pharma were up 3.36% at 211.89p.
8 May 2018 13:13
Former Amryt Pharma Non-Executive Friel Sells 8.4 Million Shares (ALLISS)
LONDON (Alliance News) - Amryt Pharma PLC on Tuesday said on Tuesday a company owned by a former non-executive director has sold 8.4 million shares in the company.Raglan Road Capital Ltd is
Read more